Shanghai Labway Clinical Laboratory Co., Ltd (SHE:301060)
China · Delayed Price · Currency is CNY 9.86
-0.11 (-1.10%)
Aug 11, 2026, 3:04 PM CST
SHE:301060 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 1,384 | 1,448 | 1,742 | 1,674 | 4,199 | 1,778 |
Revenue Growth | -16.44% | -16.88% | 4.05% | -60.13% | 136.14% | 43.62% |
Gross Profit Gross Profit Growth | 351.34 | 342.87 | 332.53 | 329.31 | 1,779 | 672.9 |
Operating Income Operating Income Growth | 56.86 | 14.89 | -62.37 | -155.55 | 1,071 | 294.15 |
Net Income Net Income Growth | 14.25 | -30.75 | -109.44 | -141.59 | 617.32 | 203.84 |
Earnings Per Share EPS Growth | 0.04 | -0.08 | -0.27 | -0.35 | 1.54 | 0.58 |
EPS Growth | - | - | - | - | 166.52% | 84.64% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Sales of in Vitro Diagnostic Products Sales of in Vitro Diagnostic Products Growth | 709.04 | 944.77 | 1,021 | 922.91 | 819.2 |
Medical Diagnostic Services Medical Diagnostic Services Growth | 738.24 | 797.17 | 646.76 | 3,259 | 947.22 |
Unallocated Other Operations Unallocated Other Operations Growth | 0.76 | 0.25 | 6.72 | 17.5 | 11.91 |
Total Total Growth | 1,448 | 1,742 | 1,674 | 4,199 | 1,778 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 846.05 | 759.5 | 828.95 | 861.2 | 665.81 | 772.89 |
Total Debt Total Debt Growth | 158.1 | 171.44 | 274.29 | 407.35 | 244.59 | 65.7 |
Net Cash (Debt) Net Cash Growth | 687.95 | 588.06 | 554.66 | 453.85 | 421.22 | 707.19 |
Net Cash Growth | 28.03% | 6.02% | 22.21% | 7.75% | -40.44% | 32.75% |
Net Cash Per Share Net Cash Per Share Growth | 1.78 | 1.53 | 1.37 | 1.12 | 1.05 | 2.01 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 369.33 | 268.85 | 216.31 | 546.99 | 84.17 | 223.51 |
Capital Expenditures CapEx Growth | -50.43 | -58.49 | -76.62 | -398.89 | -230.08 | -118.88 |
Free Cash Flow Free Cash Flow Growth | 318.9 | 210.36 | 139.7 | 148.1 | -145.91 | 104.63 |
Free Cash Flow Growth | 71.57% | 50.59% | -5.68% | - | - | -15.16% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 25.38% | 23.68% | 19.09% | 19.67% | 42.37% | 37.84% |
Operating Margin | 4.11% | 1.03% | -3.58% | -9.29% | 25.50% | 16.54% |
Pretax Margin | 4.59% | 0.73% | -5.90% | -9.15% | 21.54% | 17.88% |
Profit Margin | 1.03% | -2.12% | -6.28% | -8.46% | 14.70% | 11.46% |
FCF Margin | 23.04% | 14.53% | 8.02% | 8.85% | -3.48% | 5.88% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Dividend Per Share Dividend Per Share Growth | 0.180 | 0.180 | 0.200 | - | 0.300 | 0.300 |
Dividend Per Share Growth | -10.00% | -10.00% | - | - | 0% | - |
Dividend Yield | 1.90% | 1.99% | 2.29% | - | 1.62% | 0.92% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 270.01 | - | - | - | 12.72 | 68.24 |
P/FCF Ratio | 12.46 | 17.52 | 26.01 | 35.94 | - | 132.95 |
PS Ratio | 2.87 | 2.55 | 2.09 | 3.18 | 1.87 | 7.82 |